New Paradigm in Ocular Surface Squamous Neoplasia—Insights from a Case Report on the Use of Interferon in Treatment

Ferdinando Cione¹, Maddalena De Bernardo^1,*, Mario Graziano¹, Palmiro Cornetta², Rossella Centola³, Alessandro Caputo¹, Pio Zeppa¹, Amelia Filippelli¹
1 Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi, Salerno, Italy
2 Presidio Ospedaliero “Maria SS Addolorata”, ASL Salerno, Eboli, Piazza Scuola Medica Salernitana, Eboli, Salerno, Italy
3 Department of Pharmacy, University Hospital “San Giovanni di Dio e Ruggi D’Aragona”, Via San Leonardo, Salerno, Italy
* Corresponding Author: Maddalena De Bernardo. Email: email

Oncology Research https://doi.org/10.32604/or.2026.073113

Received 11 September 2025; Accepted 12 February 2026; Published online 27 April 2026

Abstract

Background: Ocular Surface Squamous Neoplasia (OSSN) is the most common non-melanocytic ocular surface tumor. Treatment options include surgery and topical or injectable therapies, with interferon alpha-2b (IFNα−2b) being a well-tolerated immunomodulatory agent. This case report aims to explore the use of topical IFNα−2b in a patient with multiple OSSN recurrences. Case Description: A 65-year-old woman with a history of recurrent conjunctival papilloma, confirmed as OSSN, was treated with excision and cryotherapy, followed by subconjunctival IFNα−2b injections and eventually topical IFNα−2b (3 million international units-MIU/mL, four times daily for 12 weeks) after further recurrence. Initial discomfort and redness were reported shortly after starting topical therapy, but significant lesion regression was observed. After eight weeks, complete clinical remission was achieved. Despite premature discontinuation due to drug unavailability, no relapse was observed during a 3-year follow-up. Conclusions: This case underscores the clinical effectiveness and favorable tolerability of topical interferon alpha-2b in the management of recurrent ocular surface squamous neoplasia. The achievement of durable remission after a shortened treatment course highlights its potential as a flexible therapeutic option, with meaningful implications for clinical practice, particularly in settings with limited access to biologic therapies.

Keywords

Case report; conjunctival; interferon-alpha; ocular surface; papilloma; recurrence; topical

Downloads
- Full-Text PDF
Citation Tools
- BibTex
- EndNote
- RIS

50

View
11

Download
0

Like

Progress on diagnostic and prognostic markers of pancreatic cancer
HONG YANG, WAN LI, LIWEN REN,...
The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway
SHUIZHONG CEN, XIAOJIE PENG, JIANWEN...
Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
OZAN CEM GULER, EZGI OYMAK, GOZDE...
Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α
KUO-SHYANG JENG, PO-YU CHENG,...
New perspectives on biology, disease progression, and therapy response of head and neck cancer gained from single cell RNA sequencing and spatial transcriptomics
GERWIN HELLER, THORSTEN FUEREDER,...

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

New Paradigm in Ocular Surface Squamous Neoplasia—Insights from a Case Report on the Use of Interferon in Treatment

Abstract

Keywords

50

11

0

Further Information

Guidelines

Follow Us

Join Us

Contact Us

WhatsApp:

Share Link